SNDX

Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Syndax Pharmaceuticals' Axatilimab Trial in Pulmonary Fibrosis Misses Primary Endpoint

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

H.C. Wainwright reiterates Buy on Syndax stock, $38 target

H.C. Wainwright reiterates Syndax stock Buy rating at $38 target

Jefferies reiterates Buy on Syndax stock ahead of IPF data

Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases (SNDX)

Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX)

RCS - Diaceutics PLC - Diaceutics and Syndax expand Relay partnership

UBS lowers Syndax Pharmaceuticals price target on revenue outlook

Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2026-08-05